Paloma Partners’s Theriva Biologics TOVX Stock Holding History

Paloma Partners’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-42	Closed	-$207K	–	2428
2017 Q2	$207K	Buy	+42	New	+$209K	﹤0.01%	1978
2015 Q1	–	Sell	-1	Closed	-$18K	–	1427
2014 Q4	$18K	Sell	1 -3	-75%	-$40.3K	﹤0.01%	1120
2014 Q3	$57K	Buy	+4	New	+$65K	﹤0.01%	943

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners's TOVX Position: Q3 2017 in Review

Paloma Partners sold out of Theriva Biologics (TOVX) in Q3 2017, closing a stake of 42 shares — an estimated $207K sold.

Paloma Partners first reported a position in TOVX in Q3 2014 and held it in 3 quarters. The position peaked at $207K in Q2 2017. 51 funds tracked by Wall St. Rank hold TOVX as of Q3 2017.

Paloma Partners reported no remaining Theriva Biologics position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 42 Theriva Biologics shares in Q3 2017, an estimated $207K.
Paloma Partners first reported a position in Theriva Biologics in Q3 2014 and held it in 3 quarters.
Paloma Partners's Theriva Biologics position peaked at $207K in Q2 2017.
51 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.